Literature DB >> 12964069

Lapatinib ditosylate GlaxoSmithKline.

Tracy E Kim1, John R Murren.   

Abstract

Lapatinib ditosylate, an ErbB-2 and EGFR dual tyrosine kinase inhibitor, is being developed by GlaxoSmithKline plc for the potential treatment of solid tumors.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12964069

Source DB:  PubMed          Journal:  IDrugs        ISSN： 1369-7056


  2 in total

1.  Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.

Authors:  Pallav D Patel; Pengrong Yan; Paul M Seidler; Hardik J Patel; Weilin Sun; Chenghua Yang; Nanette S Que; Tony Taldone; Paola Finotti; Ralph A Stephani; Daniel T Gewirth; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2013-09-01       Impact factor: 15.040

2.  HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression.

Authors:  Shiuh-Wen Luoh; Betsy Ramsey; Amy Hanlon Newell; Megan Troxell; Zhi Hu; Koei Chin; Paul Spellman; Susan Olson; Edward Keenan
Journal:  Springerplus       Date:  2013-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.